High on-treatment platelet reactivity in patients with ischemic stroke or transient ischemic attack
10.3760/cma.j.issn.1673-4165.2023.12.007
- VernacularTitle:缺血性卒中或短暂性脑缺血发作患者抗血小板药治疗期间血小板高反应性
- Author:
Liping ZHANG
1
;
Zengxian SUN
Author Information
1. 徐州医科大学附属连云港医院，连云港 222006
- Keywords:
Ischemic stroke;
Ischemic attack, transient;
Anti-platelet aggregation inhibitors;
Aspirin;
Clopidogrel;
Dual anti-platelet therapy;
Platelet aggregation;
Pl
- From:
International Journal of Cerebrovascular Diseases
2023;31(12):918-924
- CountryChina
- Language:Chinese
-
Abstract:
Antiplatelet drugs are the cornerstone of long-term treatment and secondary prevention for ischemic stroke/transient ischemic attack (TIA) recommended by guidelines, aimed at reducing the risk of recurrent stroke and other cardiovascular events. However, some patients with ischemic stroke/TIA may still experience ischemic events during antiplatelet therapy, known as high on-treatment platelet reactivity (HTPR), which typically occurs in patients taking aspirin or clopidogrel. This article elaborates the incidence, risk factors, and commonly used evaluation methods of HTPR in patients with ischemic stroke/TIA, and elucidates the clinical significance of HTPR in patients with ischemic stroke/TIA, and investigates the antiplatelet treatment protocol of patients with HTPR.
